• Cash outflows from operating activities increased by 11% to $3.8 million
• Research & development spend, product manufacturing and operating costs, and administration and corporate costs all increased by 16%
• Cash and cash equivalents including restricted cash as at 31 December 2024 was $8.9 million

Universal Biosensors, Inc. (ASX:UBI) has released its cash flow report (ASX Appendix 4C) and quarterly activity report for the quarter ended 31 December 2024 (Q4 2024). Key developments during Q4 2024 include:- Cash outflows from operating activities increased by 11% to $3.8 million from the previous quarter (Q3 2024 decreased by 11% on Q2) due to: - 16% increase in research & development spend - 16% increase in product manufacturing and operating costs - 16% increase in administration and corporate costs - 49% decrease in interest received- Cash outflows from investing activities decreased by 82%Cash and cash equivalents including restricted cash as at 31 December 2024 was $8.9 million. Payments of $91,000 were made for non-executive directors' fees, allowances and superannuation.